Allogeneic Hematopoietic Cell Transplantation: A Historical Perspective

Storb, Rainer

doi:10.1159/000076984

Cited by 4 publications

(3 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major complications after alloHSCT are graft failure, relapse, and graft‐versus‐host disease (GVHD). Among non‐relapse causes of mortality, approximately 50% are related to GVHD/infections 1 …”

Section: Introductionmentioning

confidence: 99%

Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III–IV and no impact on relapse and overall survival

Guidotti

Bassi

Rossi

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Objectives Early chimerism analysis is important to assess engraftment in allogeneic hematopoietic stem cell transplantations. Methods We retrospectively investigated the impact of T‐cell chimerism at day 30 in bone marrow on acute graft‐versus‐host disease (aGVHD), relapse, and overall survival in 142 adult allo‐transplanted patients. Results The majority of patients (89%) received myeloablative conditioning and 90% have undergone T‐cell replete donor graft. At day 30, 103 patients showed T‐complete chimerism with prevalence in haploidentical transplants, whereas 39 cases had CD3+ mixed chimerism, including 30 patients transplanted with HLA identical donors, and 21 with T‐cell donors<90%. T‐cell chimerism at day 30 was weakly inversely related to aGVHD grades II–IV (p = .078) with no cases of grades III–IV aGVHD in patients with CD3+ <95%. Mixed T‐cell chimerism did not impact on relapse (p = .448) and five of the seven patients who relapsed had T‐cell chimerism ≤90%. Older age and active disease at transplant had a statistically significant negative effect on overall survival (p = .01 and p = .0001, respectively), whereas mixed CD3+ chimerism did not. Conclusions T lymphocyte chimerism analysis at day +30 in bone marrow could identify allo‐transplanted patients at major risk of aGVHD grades III–IV (CD3+ donors >95%) mainly post‐myeloablative conditioning regimen.

show abstract

Section: Introductionmentioning

confidence: 99%

Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III–IV and no impact on relapse and overall survival

Guidotti

Bassi

Rossi

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Both autologous and allogeneic transplant numbers are increasing worldwide (Storb, 2004). The procedure for transplantation is complex, can cause intense psychological distress, and extreme social strain on the patient, family members, and friends.…”

mentioning

confidence: 99%

“…Hematopoietic Stem Cell Transplantation (HSCT) is standard treatment for many high risk hematologic malignancies and non-malignant diseases either as part of overall treatment or after relapse. Both autologous and allogeneic transplant numbers are increasing worldwide (Storb, 2004). The procedure for transplantation is complex, can cause intense psychological distress, and extreme social strain on the patient, family members, and friends.…”

mentioning

confidence: 99%

Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation

et al. 2013

View full text Add to dashboard Cite

Hematopoietic Stem Cell Transplantation (HSCT) is standard treatment for many high risk hematologic malignancies and non-malignant diseases either as part of overall treatment or after relapse. Both autologous and allogeneic transplant numbers are increasing worldwide (Storb, 2004). The procedure for transplantation is complex, can cause intense psychological distress, and extreme social strain on the patient, family members, and friends. There are times when the psychological and social issues can be more challenging for the health care team than the medical issues. Because HSCT is an intense and distinctive experience for patients and families and has the potential to cause prolonged psychological distress unlike other experiences with oncology patients, the issues unique to this population warrant special attention (Andrykowski, Brady, Henslee-Doeney, 1994, Andrykowski, 1994).

show abstract

Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation

et al. 2014

View full text Add to dashboard Cite

To evaluate the correlation between chimerism status and acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation. Chimerism of peripheral blood of 124 patients was monitored at regular intervals post-transplant. The chimerism of 124 post-transplant cases of CD3(+)T lymphocytes, 107 cases of CD3(-)CD56(+)CD16(+)NK lymphocytes, 49 cases of CD15(+) granulocytes, and 27 cases of CD19(+)B lymphocytes sorted by fluorescence-activated cell sorter were analyzed by polymerase chain reaction amplification of short tandem repeats. Differences were found in the time between establishment of full donor T-cell chimerism and the occurrence of aGVHD (P = 0.035, two related samples test). Patients with ≥69 % donor chimerism on day +7 in T-cells had higher rates of aGVHD. This study may provide a rational basis for treatment with adoptive immunotherapy at an earlier time, such as day 7 after SCT, than at present to prevent aGVHD.

show abstract

Allogeneic Hematopoietic Cell Transplantation: A Historical Perspective

Cited by 4 publications

References 96 publications

Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III–IV and no impact on relapse and overall survival

Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III–IV and no impact on relapse and overall survival

Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation

Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation

Contact Info

Product

Resources

About